NR3C2 and obstructive sleep apnea syndrome: Extensive experimental IH and SF studies are needed, evaluating multiple in vivo and in vitro cardiovascular parameters while using different MR antagonists as well as specific transgenic animals with cell-specific targeted disruption of MR, to better understand the mutually dependent effects and interactions between RAAS and OSA and further explore the viability of MR-targeted treatment on OSA cardiovascular outcomes.